Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist research peptide — the most-anticipated next-generation metabolic compound, in a Vivaprime prefilled pen.
- Total mass
- 30 mg
- Volume
- 3 ml
- Concentration
- 10.00 mg / ml
- Format
- Prefilled penReady to use — no reconstitution, no BAC water, no syringe calculation
- Dose increment
- 0.1 mgDial-click precision
- Storage
- 2–8 °C refrigeratedDo not freeze
- Manufacturing
- EU cGMP facilityReleased against pre-registered specs
The pen ships sealed and pre-dosed. Dial, inject, store refrigerated. No reconstitution, no transfer loss, no volume calculation.
- No reconstitution. Skip bac water, syringes, swirl-and-wait.
- 0.1 mg dose resolution. Mechanical counter, not syringe-barrel guessing.
- Sealed single cartridge. No rubber septum re-entries, no exposed plunger.
- Package-to-dose < 60 s. Pull cap, dial, record. No prep workflow.
All products are intended for laboratory research use only. Not for human or animal consumption, diagnostic, or therapeutic use.
Retatrutide — what researchers say
No reviews yet. Be the first to post one below — we moderate every review before publishing.
Retatrutide is the first peptide to combine GLP-1, GIP, and glucagon receptor agonism in a single molecule. A research-context primer on mechanism, published literature, and how it compares to semaglutide and tirzepatide.
Read the primer →Commonly studied with Reta
AOD-9604
AOD- Dose
- 30 mg
- Purity
- —
- $ / mg
- $8.30/mg
Modified hGH fragment 176–191 research peptide — widely studied in adipose-tissue and lipolytic-pathway research, in a Vivaprime prefilled pen.
5-Amino-1MQ
- Dose
- 100 mg
- Purity
- —
- $ / mg
- $2.79/mg
5-Amino-1MQ small-molecule NNMT-pathway inhibitor research compound — complements NAD+-salvage research. Vivaprime prefilled pen.
Adipotide
- Dose
- 30 mg
- Purity
- —
- $ / mg
- $9.30/mg
Experimental pro-apoptotic peptide studied for its selective action on the vasculature supplying white adipose tissue. Prefilled in a ready-to-use pen for research use only.
Cagrilintide
Cagri- Dose
- 30 mg
- Purity
- —
- $ / mg
- $11.63/mg
Long-acting amylin-receptor analog studied alongside GLP-1 agonists in metabolic research. Prefilled in a ready-to-use 30 mg pen.
Quick answers about Reta
- Is Reta pre-mixed and ready to use, or do I need to reconstitute it?
- Retatrutide ships as a sealed prefilled pen. No reconstitution, no bacteriostatic water, no syringe draw. Each pen is pre-dosed with dial-click increments at the factory under EU cGMP release specifications.
- How is Reta tested and what's on the Certificate of Analysis?
- Every batch is released against a written specification. Identity is confirmed by HPLC-MS plus Amino Acid Analysis; purity is measured by reverse-phase HPLC; residual solvents per ICH Q3C; endotoxin (LAL) per USP. The latest batch and its % purity are published on the product page. Full COA history is available on our lab results page.
- How should Reta be stored?
- Refrigerate 2–8 °C. Do not freeze. Protect from direct light.
- How is Reta shipped?
- Cold-chain shipped within the US with ice packs and insulated packaging. Orders ship within 1 business day and most US addresses arrive in 2–3 business days. Orders over $300 ship free.
- Is Reta sold for human use?
- No. Retatrutide is sold strictly for in vitro research and laboratory use by qualified professionals. It is not intended for human consumption, therapeutic, or diagnostic use. This research-use framing is enforced in all product materials and operational documentation.
- How many doses does a 30 mg / 3 ml pen pen of Reta deliver?
- The exact number of doses depends on the research protocol's per-dose quantity. Pens dial in 0.1 mg increments and total mass per pen is shown on the product page. Divide total mass by your planned per-dose mass to estimate doses.